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Failure modes of thoracic endografts can be broadly categorized as those that typically occur early in the perioperative
period and those that occur during late follow-up. In the former category, failures principally involve delivery,
deployment, and conformation to the local anatomy. In the postoperative period, failures can manifest as endograft
collapse, component separations, and metallic fractures and fabric tears. Some of these events are preventable with careful
case selection, planning, and procedural technique, but others require active management with advanced endovascular or
surgical adjuncts. No endograft system is immune from these problems. Endograft failure is an equal-opportunity hazard,
which underscores the absolute need for diligent, long-term follow-up. (J Vasc Surg 2009;49:792-9.)Careful patient selection and case planning is critical to the
early and late success of thoracic endovascular aortic aneurysm
repair (TEVAR). It can be said that 90% of the battle is won or
lost before stepping into the operating room. Although repair
of an uncomplicated mid-descending thoracic aneurysm is
fairly straightforward, most thoracic pathologies lie close to
the arch vessels proximally or mesenteric vessels distally, or
both. Meticulous attention to detail and proficiency in ad-
vanced endovascular skills are required to safely complete
these procedures and avoid themyriad of potential pitfalls that
can lead to lethal complications.
Experience with abdominal endografts is useful, but
TEVAR is sufficiently different due to the extreme tortuos-
ity of the thoracic aorta that is not easily corrected with stiff
wires, the greater hemodynamic forces in the arch, the
remote location of the pathology relative to the remote
entry site, and the significantly increased risk of iatrogenic
dissection and aortic injury that is not readily surgically
accessible.1
Thoracic endografts typically fail either in the early
perioperative period or during late follow-up. In the former
category, failures principally involve delivery, deployment,
and conformation to the local anatomy. In the postopera-
tive period, failures can manifest as endograft collapse,
component separations, and metallic fractures and fabric
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792tears. This article will discuss some of these failure modes
and methods for their prevention and management.
EARLY FAILURES
Inability to advance delivery catheter. Thoracic an-
eurysmal disease frequently involves tandem segments of
severe aortic tortuosity that are not readily corrected with
stiff guidewires. The ability to push the guidewire is lost
with each successive turn of the bend. Most delivery cath-
eters have a stiffness transition between the relatively stiff
proximal end, where the endograft is loaded, and the distal
shaft. This forms a flexion point where the delivery catheter
can bend at the vertex of an angulation. In certain severe
cases, because the vector forces are not coaxial to the
delivery catheter, continued pushing of the catheter can
paradoxically retract the proximal end of the device. Aortic
tortuosity can be partially overcome with use of superstiff
“buddy wires” or even “buddy dilators,” where a stiff
dilator of an introducer sheath is inserted from the con-
tralateral femoral artery (Fig 1).
The only method of reliably overcoming severe aortic
tortuosity is to use a transbrachiofemoral wire (Fig 2). The
transbrachiofemoral wire represents the ultimate form of a
stiff rail because it provides two points of fixation. In this
technique, a 6F 65-cm guide sheath is inserted through the
right brachial artery, and a long guidewire is directed into
the descending thoracic aorta, snared, and brought out
through the femoral sheath. Both ends are secured. The
delivery catheter is advanced over this guidewire while both
ends are held taught.
For proximal lesions, the nose cone of the delivery
catheter sometimes will need to be advanced into the
innominate artery while backing up the 6F guide sheath.
This guide sheath is important to prevent inadvertent aortic
injury or dissection with the guidewire (“cheese-cutter”
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can also be used to obtain control angiograms before or
during deployment of the endograft.
Unintended device movement. Unintentional move-
ment of the endograft can occur during or after deploy-
ment and result in inadvertent coverage of vital branch
Fig 1. Severe aortic tandem tortuosity is partially corrected using
a “buddy” dilator inserted over a superstiff Lunderquist guidewire
(Cook Medical, Bloomington, Ind) from a contralateral femoral
access.
Fig 2. In the transbrachiofemoral wire technique, a gui
guide catheter or sheath and snared from a femoral appr
applying firm tension at both ends. The long guide sheath
the deployment.vessels or geographic miss of a part or the entire landing
zone. Two mechanisms of endograft deployment are used
by all of the commercially manufactured thoracic devices.
The most common mechanism is the pin-pull method of
unsheathing the self-expanding endograft, similar to de-
ployment of a peripheral stent. Some delivery systems use a
torque-transfer mechanism to reduce the actual pull force
needed to unsheathe the device, especially in tortuous
anatomies (Fig 3). When the proper dynamic pin-pull
tension is not applied, the device can migrate forward,
especially during the initial few centimeters of deployment,
or retract backwards in tortuous anatomies, where the
stored potential energy of the stent graft can be released
suddenly.
e is introduced from the right brachial artery over a long
The thoracic endograft is advanced over the guidewire,
be used to inject contrast for control angiography during
Fig 3. The Valiant thoracic endograft (Medtronic, Santa Rosa,
Calif) has a deployment handle that rotates in a counterclockwise
manner to unsheathe the endograft. This significantly helps to
overcome the high frictional forces required to deploy this en-
dograft using standard pin-pull mechanism.dewir
oach.
can
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the resistive forces of the constraining sheath against the
endograft internally and the friction of a tightly fitting arterial
wall externally must both be overcome. This problemmay be
partially obviated by use of a conduit. When the forces in-
volved are understood, inadvertent movement of the en-
dograft can be avoided by firmly “pinning” or even applying
slight backward tension on the delivery catheter at the begin-
ning of deployment, and once the proximal segment is firmly
seated, the force is reversed and slight forward pressure is
applied while the deployment is completed. This allows the
distal segment to provide the necessary slack to the endograft
as it conforms to the outer curve and reduce the risk of
retraction of the proximal attachment site.
The TAG endograft (W. L. Gore and Assoc, Flagstaff,
Ariz) is a device with a unique, single-step deployment
mechanism. The stability of the deployment depends on
fixation of the device against the outer wall of the thoracic
aorta. Owing to its unusual deployment from its middle
portion and outward, the first point of contact (and fixa-
tion) may be in the middle of the aneurysm sac. In tortuous
anatomies, especially near the arch, the device retracts from
both the proximal and distal ends as the device conforms
along the outer contour of the aorta, starting from its initial
midpoint of fixation. This makes it almost impossible to
control where the proximal or distal end, or both, of the
endograft will land. This unpredictability is proportional to
Fig 4. The crowns of the proximal bare stent of the Valiant
thoracic endograft (Medtronic, Santa Rosa, CA) are everted along
the inner curve of the arch as the device is pushed against the outer
curve by the delivery system.the length of the device. Therefore, this uncertainty may beminimized by using the shortest device (10 cm) in critical
areas. On the other hand, using this technique necessitates
use of at least a second device when a single device could
have been used based on length of the lesion alone.
Another mechanism of device migration can occur
from actual movement of an endograft that has been just
deployed either during passage of a second endograft
through it or during removal of the delivery system. Fortu-
nately, this is a rare occurrence, but under the wrong set of
circumstances, one edge of the endograft can interact with
another edge of the delivery system in such a way that the
endograft can actually be pushed upwards, dragged distally,
or even cause the device to be completely invaginated
within itself.
Occasionally, when the first device is deployed within a
large sac that is located near the apex of a tight curve (eg,
distal arch) and most of the endograft is essentially floating
in lumen of the aorta, the nose cone of a second device can
inadvertently push the middle segment of the first device
against the outer aorticwallwhile trying tomake the curve and
pull out the endograft from its proximal or distal attachment,
or both. To avoid this problem in severely angulated anat-
omies a transbrachiofemoral wire may be used, which can
effectively guide the delivery system along the convexity of
a bend away from the outer wall, and reduce the risk of
distraction of the endograft ends.
Device misdeployment. As previously mentioned,
most of the commercial devices use a pin-pull method of
deployment whereby the self-expanding endograft is slowly
unsheathed in a proximal to distal manner. Fortunately,
deployment failures are rare, but when they do occur, they
are in the setting of severe aortic tortuosity and near the
distal arch. One type of misdeployment has been variably
termed spring flip, misaligned deployment, or bare-spring
eversion. Although the exact incidence of this failure mode
is uncertain, it has been associated with the Talent thoracic
and Valiant (Medtronic Cardiovascular, Santa Rosa, Calif)
endografts that have a proximal bare-spring (Free-Flo)
configuration. Review of intraoperative images showed ec-
centric flaring of the bare stent component of the proximal
main device due to apposition of the leading end of the
Fig 5. The tip-capture mechanism of the Relay thoracic en-
dograft (Bolton Medical, Sunrise, Fla). The tips of the proximal
bare stent in this device remain constrained (“captured”) until the
rest of the endograft is fully deployed. It is released by a separate
mechanism as the final step of the deployment sequence.delivery system against the outer curve (Fig 4). This failure
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volve significant tortuosity, especially in the distal arch,
small radius curvature, and larger diameters. To date, no
adverse clinical sequelae from these events have been re-
ported.
Once a bare-spring eversion occurs, there is no easy
remediable solution, and the best management is preven-
tion. Some technical tips that have been suggested include
avoidance of deployment in adverse anatomies, deploy-
ment proximal to the intended landing zone and pulling
backwards, and rapid deployment of the first one or two
covered stents to tubularize the device to force the bare
crowns near the inner curve against the aortic wall. None of
these technical solutions is optimal, and the only reliable
method of prevention is incorporation of a tip-capture
mechanism in the delivery system (Fig 5).
Although the TAG device does not involve an unsheath-
ing process, instances have occurredwhere the device failed to
deploy fully.2 Unlike conventional pin-pull mechanisms,
which in cases of failure simply require removal of the unde-
ployed delivery system, when the TAG device fails to deploy
either fully or partially, significant adjunctive techniques may
be required to salvage the problem.
In all the reported cases of partial TAG deployment, the
proximal end of the endograft had failed to deploy. These
were associated with longitudinal compression of the un-
deployed endograft against the distal olive tip, which un-
coupled the proximal constraining mechanism from the
rest of the endograft. In these situations, the open distal
end of the endograft was catheterized similar to the cathe-
terization of the contralateral gate of an abdominal bifur-
cated endograft, an 0.014-in guidewire insinuated between
the undeployed endograft and the central shaft, and the
space serially dilated starting with a 3-mm coronary balloon
up to a 10- or 12-mm balloon inflated to 8 to 10 atmo-
spheres, forcibly breaking the constraining expanded poly-
Fig 6. Left, A partially deployed TAG endograft (W.
end still constrained on the delivery catheter. Right, A
constraining expanded polytetrafluoroethylene suture.tetrafluoroethylene suture (Fig 6).Device infolding. Most self-expanding aortic en-
dografts are oversized 10% to 20% above the true inner or
outer wall diameter to obtain an adequate friction fit for seal
and fixation at the landing zones. The larger-diameter
devices typically fall in the lower end and smaller devices are
oversized towards the higher end of this range. Oversizing
beyond this range may result in infolding of the endograft
(Fig 7). Infolding near the proximal or distal landing zone
may lead to a type I endoleak, stent fatigue, luminal flow
disturbances, and thrombotic complications.
In anatomies that have discrepant diameters between
the proximal and distal landing zones, the endograft is
typically selected according to the larger of the two aortic
diameters, which means that at the smaller end, the en-
dograft will be oversized significantly beyond the upper
range of recommended device oversizing. One extreme
example of this scenario occurs during off-label treatment
of type B/III aortic dissections. The endograft is typically
sized to the undissected segment of the aortic arch, but the
rest of the device is deployed in a narrowed true lumen.
Even if this lumen expands, it does not expand to the size of
the reference arch diameter.
Prevention of this failure mode includes following the
manufacturer’s sizing guidelines, use of tapered devices,
and stepwise upsizing of the endografts either proximal to
distal or vice versa (shingling). The ideal solution, however,
is a tapered or reverse-tapered endograft configuration with
a broader range of diameter gradients (current devices only
allow for a 4-mm taper) and improved stent designs that
allow for a wider tolerance for oversizing and circumferen-
tial radial expansion.
Arch conformation. Nearly every device has a mini-
mum radius of curvature to which it can conform, and
below which malapposition of the endograft to the inner
curve can occur (Fig 8). The inner curve acts as a fulcrum
over which the proximal edge of the endograft hangs over
re and Assoc, Flagstaff, Ariz) is shown with its proximal
m angioplasty balloon was used to forcibly break theL. Go
12-mthe ascending aorta. This can lead to a type I endoleak and
men
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ment include identification of the proper landing zone
beyond the simple considerations of its length and diame-
ter. In the case of a proximal descending lesion, if there is
adequate length of nonaneurysmal aorta, the endograft
should be deployed sufficiently proximal to the apex of the
arch, even if the left subclavian artery must be covered, or
entirely distal (down slope) to it so that the device lands in
Fig 7. Examples of (A, B) proximal and (C) middle th
oversizing. Note the severe infolding of the proximal seg
Fig 8. Malapposition of an endograft along a tight inner curve of
the arch is shown.Note how the device has completely lifted off the
aortic wall (yellow dotted line) and can become a source of a type IA
endoleak.a parallel segment of the aorta (Fig 9).Alternatively, device-specific improvements in terms of
stent fabric construction and delivery system design are
clearly needed to remedy this failuremodemoving forward.
Although manufacturers have used a proximal bare stent to
help align the first covered (sealing) stent along the inner
curve, there have been rare cases of aortic perforations and
retrograde type A dissections that were associated with the
use of bare stents to repair type B aortic dissections.3
LATE FAILURES
Endograft collapse. Proximal endograft collapse
(compression) has been most commonly reported with the
TAG device.4,5 Indeed, as of the manufacturer’s 2008
Annual Clinical Update, at least 95 cases had been con-
firmed. This failure mode has been associated with deploy-
ment of the endograft near the distal arch with a small
radius of curvature and excessive oversizing. As described,
the endograft fails to conform to the inner curve of the
arch, which acts like a fulcrum over which the endograft
hangs like a ledge. The high aortic blood flow can push up
against this ledge and result in a complete collapse of the
endograft and a type I endoleak (Fig 10). This can be
managed with placement of a bare metal balloon-expand-
able stent (eg, P4010, P5010) or another endograft within
the collapsed segment. The long-term safety of this ap-
proach has not been established, and occurrence of this
complication should be considered an indication for surgi-
cal conversion.
As a technical matter, deployment of a large-diameter
balloon-expandable stent near the arch is not trivial. The
stent can slip off the balloon, be asymmetrically crushed by
the balloon during expansion, and migrate from the target
location due to the pulsatile forces present near the proxi-
mal aorta. Significant reduction of blood pressure is fre-
quently required for accurate deployment.
Component separation. Component separation is a
well-recognized late failure of all modular aortic endograft
c endograft infolding are shown secondary to excessive
t, which almost bisects the flow lumen into two halves.oracisystems. Close surveillance and inspection of component
JOURNAL OF VASCULAR SURGERY
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to the apex of the arch. The bottom panels illustrate deployment near the apex resulting in malapposition of the
endograft along the inner curve.Fig 10. Complete collapse of the TAG endograft (W. L. Gore and Assoc, Flagstaff, Ariz) at the proximal attachment site.
stent
cation
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mum intensity projection reconstructions of computed to-
mography data sets are critical to the overall long-term
treatment algorithm after TEVAR. This obviously requires
recognition of the terminal markers of the endograft com-
ponents, and those devices that have easily visible markers
facilitate this task. Junctions that lie near a curve and within
the main aneurysmal segment of the thoracic aorta have the
greatest risk of separation. Endograft movement is depen-
Fig 11. Component separation. Left, At the predisch
noted between the proximal and distal components.Mid
only a two-stent overlap.Right, This patient underwent
follow-up showed further separation with less than one-
Fig 12. Longitudinal bar fracture in the first-generatio
feature has been eliminated from the subsequent modifident on the pulsatility of the blood flow and the intralumi-nal and extraluminal (intrasaccular) pressure gradient. Un-
der a specific set of hemodynamic and anatomic conditions,
the components that initially coursed along the inner wall
will continue to bow out towards the outer curve until the
device hits the opposite wall of the aorta or separates
completely (Fig 11).
Prevention is always easier and safer than treatment.
Introduction of some redundancy in the endograft path
during the original deployment, generous overlap (5 cm)
computed tomography scan, a three-stent overlap was
t 12-months, the separation has started to occur, leaving
ve revision with a bridging endograft after his 24-month
overlap but without an endoleak.
G device (W. L. Gore and Assoc, Flagstaff, Ariz). This
of the endograft.arge
dle,A
electin TAbetween devices, and prophylactic correction of impending
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cation. The treatment is fairly straightforward, with inser-
tion of a bridging endograft between the two endografts.
Wireform fractures and fabric tears. Stent fractures
and fabric tears can occur at any point during the postop-
erative follow-up period. Mechanically, wireform fractures
are mainly due to metal fatigue from repetitive torsional
and bending motions and high loads. They have been more
commonly associated with straight elements of the en-
dograft construction, such as longitudinal connecting bars
intended to impart column strength. Fabric tears have
occurred from surface erosion by repetitive motion of cal-
cific lesions along the luminal contact surface or the sharp
edge of a fractured stent or the connecting bar. Despite the
frequency of its occurrence in some of the earlier endograft
designs, the incidence of serious adverse events associated
with this failure mode has been relatively infrequent (Fig
12).
Wireform fractures are typically clinically silent and
seen as an incidental finding on follow-up x-ray imaging.
Fabric tears are more serious and may present with acute
aneurysm-related symptoms and, by definition, a new type
III endoleak. Diagnosis of a fabric tear, however, is really
one of exclusion. The source of an endoleak occurring in
the vicinity of an endograft junction or visible intercostal
vessel can be difficult to establish. Fortunately, as long as a
type II endoleak can be ruled out, treatment is the same
with placement of another endograft.
CONCLUSIONS
There are multiple failure modes that can affect the
short-term and long-term safety and performance of athoracic endograft. Some of these failure modes require
prevention by careful case selection and meticulous atten-
tion to detail, and others require active management using
adjunctive endovascular and other techniques. Although all
devices are at risk, some failures are more specific to one
device over another and can only be remedied with im-
provements in design and construction.What may not have
been fully appreciated in the past, but which is now well
recognized today, is that the delivery system is as important
as the endograft in determining the early and late outcomes
of the therapy. No matter how effective the endograft, if it
cannot be delivered in a safe, consistent, and reliable man-
ner, the repair will be ineffective. Therefore, research and
development in this therapy must be encouraged in both
fronts.
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